T2 Biosystems Earnings Call Transcripts
Fiscal Year 2024
-
Q3 2024 revenue grew 34% year-over-year, driven by strong sepsis test and international instrument sales. Exclusive U.S. distribution with Cardinal Health and a co-marketing deal with Precision Inc. are expected to accelerate growth, with new product launches and FDA submissions planned for 2025.
-
Exclusive U.S. distribution with Cardinal Health and a new AI collaboration with Precision Inc. are expected to drive growth and expand market reach. Q3 revenue rose 35% year-over-year, with strong sepsis panel sales and new FDA clearance for pediatric use.
-
Presented unique FDA-cleared diagnostics for rapid sepsis detection, with strong clinical evidence of faster treatment and reduced hospital stays. Operational improvements and global expansion support record revenue growth, with new products and partnerships planned for 2024.
-
A cutting-edge diagnostic platform enables rapid, direct-from-blood sepsis detection, bypassing slow and supply-constrained blood cultures. Recent clinical studies show significant reductions in time to targeted therapy and hospital stays. Strategic partnerships, new product launches, and operational improvements are expected to drive growth and financial stability.
-
Sepsis remains a critical and costly challenge for hospitals, with rapid, culture-independent diagnostics offering significant clinical and financial benefits. Key growth drivers include global expansion, new product launches (T2Lyme, T2Resistance), and a major US partnership, with strong second-half 2024 performance expected.
-
Q2 2024 saw record sepsis test revenue and strong international expansion, with 27% year-over-year growth and significant cost reductions. The company is pursuing a major U.S. partnership, launching new products, and expects 49–64% revenue growth for 2024.